A5007982458- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Screening and Detection
- Cervical Cancer and HPV Research
- Pancreatic and Hepatic Oncology Research
- Surgical site infection prevention
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Angiogenesis and VEGF in Cancer
- Multiple and Secondary Primary Cancers
- Inflammatory Biomarkers in Disease Prognosis
- Gastrointestinal Tumor Research and Treatment
AC Camargo Hospital
2016-2025
Universidade de São Paulo
2018
Instituto do Câncer do Estado de São Paulo
2018
369 Background: Gastric (GC) and pancreatic cancer (PC) have poor prognosis representing major public health challenges, particularly in Latin America. Real-world data are limited. GASPAR (LACOG 0222) study addresses this gap by creating a multicenter database to analyze epidemiological, clinical, pathological data, treatments, outcomes for patients (pts) with GC PC. Methods: This retrospective prospective observational cohort enrolled pts from 7 research sites 3 LATAM countries...
497 Background: Patients with LAGC should undergo perioperative chemotherapy and surgery. Lauren’s diffuse subtype signet-ring cell carcinoma have been linked to worse outcomes chemoresistance in this setting. This study aimed assess the impact of classification on response neoadjuvant prognosis LAGC. Methods: analysis involved adult patients from a prospectively collected gastric cancer database who had histologically confirmed received curative-intent were classified into two groups...
Abstract Effective treatment for advanced and metastatic tumors remains a major clinical challenge. Chemotherapy has an objective response rate of 40%, reliable predictive biomarkers to guide are lacking. Global implementation Functional Precision Oncology (FPO) offers promising, personalized approach predicting tumor response, with potential improve patient outcomes, optimize resource use, promote equity across diverse geographic regions. This study aims establish validate functional...
Abstract The 2019 Word Health Organization (WHO) subclassified grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into carcinoma (NEC) or tumours (G3 NET) based on morphology and proliferation. Yet, few data exist molecular profiles for G3 NEN. We compared clinicopathological characteristics of these two groups. retrospectively reviewed consecutive GEP NEN patients had their tumour tissues reviewed, reclassified as per the WHO 2019, analyzed by a next‐generation...
Mechanisms of resistance have been described during disease progression (PD) for patients under treatment with anti-EGFR plus chemotherapy (CT). The aim our study was to evaluate efficacy rechallenge (ReCH) and reintroduction (ReIn) in metastatic colorectal cancer (mCRC).This is a retrospective analysis mCRC that previously received + CT interrupted therapy due PD the ReCH group other reasons ReIn group. We aimed describe progression-free survival (PFS), overall (OS) response rate (RR) after...
Hyperthermic intraperitoneal chemotherapy (HIPEC) has been associated with improved survival when compared surgery alone for non-metastatic gastric cancer patients in randomized trials and meta-analyses. However, little evidence is available regarding the use of HIPEC nonmetastatic who are treated perioperative radical surgery. The aim this study was to investigate putative benefit subgroup surgery.This a retrospective cohort that included gastroesophageal junction were curative resection...
The standard treatment for localized squamous-cell carcinoma of the anal canal is definitive chemoradiotherapy. A meta-analysis published studies conducted by our group showed significantly lower rates disease-free survival (DFS) and overall at 3 years among HIV-positive patients. We aimed to compare detailed outcomes between groups -negative patients.We performed a retrospective multicenter study comparative cohort consecutive patients with histologic diagnosis who received Patients'...
Background: Nearly 30% of neuroendocrine tumors (NETs) have evidence immunohistochemical (IHC) expression estrogen (ER) and/or progesterone (PR) receptors. Therefore, targeting ER/PR may offer an effective NET-directed treatment to select patients. Methods: We conducted a multicenter Simon two-stage single-arm phase II trial tamoxifen in patients with metastatic, progressive NETs. Eligible had positive IHC ER PR ⩾ 1%. Prior therapy somatostatin analogs was required for...
Tumor-infiltrating lymphocytes (TILs) represent a host-tumor interaction, frequently signifying an augmented immunological response. Nonetheless, implications with survival outcomes in patients colorectal carcinoma liver metastasis (CRLM) warrant rigorous validation. The objective was to demonstrate the association between TILs and CRLM.
Background: Tumour budding (TB) refers to loss of tumour cohesiveness and is defined as isolated cells or a cell cluster up four at the microscopic analysis.The International Budding Consensus Conference (ITBCC) in 2016 proposed scoring system standardise pathology evaluation TB colorectal cancer (CRC) high (H), intermediate (I) low (L) TB.Objective: To evaluate recurrence-free survival (RFS) stage II CRC patients per ITBCC classification associations between clinical pathological...
Patients with stage I gastric cancer are considered to have an exquisite prognosis. Nonetheless, the fact that some patients experience disease relapse highlights a subgroup might benefit from multimodality treatment. We aimed evaluate survival of and look for harbingers recurrence.We looked treated exclusively surgery 1996 2015. The competing risks method was used allow concurrent causes mortality. Also, we calculated subdistribution hazards (SH) reveal factors associated recurrence death...
CAPOX regimen is a standard option in stage III adjuvant colon cancer. Gastrointestinal toxicity well described with fluoropyrimidine regimens and can be life-threatening. Identification of risk factors associated severe gastrointestinal may help clinicians when choosing the regimen.We retrospectively analysed 61 patients treated CAPOX. Our primary objective was to estimate incidence chemotherapy-induced enterocolitis among A secondary describe main demographic clinical characteristics these...
e16086 Background: The role of HER2 positive (HER2+) as a prognostic biomarker for gastric/gastroesophageal junction cancer (G-GEJC) is controversial. Recently, the HER2-low (HER2l) concept has emerged and proved to predict response trastuzumab deruxtecan in metastatic scenario. Data on HER2l value are missing. Methods: All consecutive patients with G-GEJC, tested primary tumor or tissue before initiating first-line therapy at A.C. Camargo Cancer Center, were retrospectively recruited....
88 Background: While patients (pts) with colorectal cancer (CRC) treated CAPOX (capecitabine and oxaliplatin) may experience severe diarrhea, risk factors for this toxicity remain undetermined. We have previously shown that concurrent use of angiotensin receptors blockers (ARB), a known inhibitor TGF-B which is important gut mucosa proliferation, significantly increased the diarrhea and/or enterocolitis. Here we conducted larger multicenter study to validate finding, adjusting other factors....
413 Background: Gastric cancer (GC) is the fourth leading cause of deaths globally. There a paucity real-life data on GC in Brazil. Our study aimed to evaluate survival trends gastric adenocarcinoma (GA) large center Brazil during 2000-2017. Methods: Based our Hospital Cancer Registry Database, all individuals diagnosed with GA between 2000 and 2017, treated at A.C. Camargo Center, were retrospectively included. The primary objectives describe patient demographics, clinicopathological...
414 Background: The role of primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) for patients locally advanced gastric cancer (LAGC) treated FLOT is currently unknown. Although original FLOT4 study did not recommend PP, the use G-CSF common in clinical practice to avoid serious complications. However, its associated increased financial costs. Methods: This a retrospective, single-institution study. We included pathologically confirmed LAGC who received perioperative...